Detail page

Knowledge Web

Person

Winfried Wels

Name	Winfried Wels
Place	Frankfurt am Main (Wirkungsort) Deutschland
Gender	männlich
Academic degree	Prof. Dr.
Variant	Winfried S. Wels
Related	Georg-Speyer-Haus
Source	Webseite: https://dktk.dkfz.de/en/research/dktk-researchers/database-researchers/details/257/1886 (Stand: 27.04.2023)
Record type	Person
GND-Identifier	128720452X
Record ID	128720452X
Involved in show all Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies Entwicklung bispezifischer Antikörper für die zielgerichtete Eliminierung von Tumorzellen durch natürliche Killerzellen Etablierung eines Organoid-Modells des ErbB2-positiven Mammakarzinoms zur Evaluierung einer zielgerichteten Immuntherapie mit CAR-NK-Zellen GD2-spezifische CAR-NK-Zellen für die adoptive Krebsimmuntherapie Correction: Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Winfried Wels

Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial

Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies

Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies

Entwicklung bispezifischer Antikörper für die zielgerichtete Eliminierung von Tumorzellen durch natürliche Killerzellen

Etablierung eines Organoid-Modells des ErbB2-positiven Mammakarzinoms zur Evaluierung einer zielgerichteten Immuntherapie mit CAR-NK-Zellen

GD2-spezifische CAR-NK-Zellen für die adoptive Krebsimmuntherapie

Correction: Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting